Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 3/20 | 0.55 |
| ▸ | MMP12 | P39900 | 3/20 | 0.55 |
| ▸ | MMP13 | P45452 | 3/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP7 | P09237 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13281777 | 0.83 | CA2 (0.57) | MMP8MMP13MMP1KMT2ACA2 | |
| SCHEMBL15754219 | 0.79 | L3MBTL1 (0.64) | MMP8MMP12MMP13MMP1MMP7 | |
| SCHEMBL3836194 | 0.78 | MMP8 (0.58) | MMP8MMP12MMP13MMP1MMP7 | |
| SCHEMBL426661 | 0.78 | IDO1 (0.56) | MMP8MMP12MMP13MMP1MMP7 | |
| SCHEMBL6488752 | 0.77 | IDO1 (0.63) | MMP8MMP12MMP13MMP1MMP7 | |
| SCHEMBL8907383 | 0.75 | MEN1 (0.60) | MMP8MMP12MMP13MMP1MMP7 | |
| SCHEMBL4170793 | 0.75 | MMP12 (0.82) | MMP8MMP12MMP13MMP1MMP7 | |
| SCHEMBL9002519 | 0.75 | MMP8 (0.59) | MMP8MMP12MMP13MMP1MMP7 | |
| SCHEMBL19798388 | 0.74 | MMP8 (0.54) | MMP8MMP12MMP13MMP1MMP7 | |
| SCHEMBL8987446 | 0.73 | IDO1 (0.59) | MMP8MMP12MMP13MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316832-B1 | Cyclopamine analogues and methods of use thereof | INFINITY PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-8236956-B2 | Cyclopamine analogues and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20110166353-A1 | Cyclopamine Analogues and Methods of Use Thereof | ROYALTY SECURITY, LLC | 2011-07-07 | — | — | US | disclosed |
| US-7875628-B2 | Anticancer agents; psoriasis; prevent activation of hedgehog gene passageways | INFINITY DISCOVERY, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875628-B2 | Anticancer agents; psoriasis; prevent activation of hedgehog gene passageways | INFINITY DISCOVERY, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080269272-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | ROYALTY SECURITY, LLC | 2008-10-30 | — | — | US | disclosed |
| US-20080269272-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | ROYALTY SECURITY, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7407967-B2 | Cyclopamine analogues and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407967-B2 | Cyclopamine analogues and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070191410-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | ROYALTY SECURITY, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191410-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | ROYALTY SECURITY, LLC | 2007-08-16 | — | — | US | disclosed |
| US-7230004-B2 | Cyclopamine analogues and methods of use thereof | INFINITY DISCOVERY, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230004-B2 | Cyclopamine analogues and methods of use thereof | INFINITY DISCOVERY, INC. (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191410-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | SHH, SMO, GLI1 | MMP8 4136/4885MMP12 3411/4885MMP13 3746/4885 |
| US-20110166353-A1 | Cyclopamine Analogues and Methods of Use Thereof | SHH, SMO, GLI1 | MMP8 4136/4885MMP12 3411/4885MMP13 3746/4885 |
| US-20080269272-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | SHH, SMO, GLI1 | MMP8 4136/4885MMP12 3411/4885MMP13 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.